ANIX - מחיר רכישת החברה anixa.com

This daily price chart illustrates the enterprise value of Anixa Biosciences, Inc. (ANIX), which stands at 99.76. The business relies on CAR-T system testing results and breast tumor diagnostics to generate royalties. High growth potential is driven by the development of anti-cancer vaccines with the capacity for mass production. The environmental profile is limited to laboratory safety and the transition to electronic document management.

Investors assess the operational strength of assets through the sum of market capitalization and debt minus cash, which determines the actual cost of acquiring a business. An analysis of the company's total fundamental value allows for a comparison of this metric with the organic growth model of Anixa Biosciences (ANIX), where the absence of M&A and a focus on asset licensing confirm financial stability and investment attractiveness.